Loading…
Efficacy and Safety of Weekly Dalbavancin Therapy for Catheter-Related Bloodstream Infection Caused by Gram-Positive Pathogens
Background. Catheter-related bloodstream infections (CR-BSIs) are associated with substantial mortality, prolongation of hospital stay, and increased cost of care. Dalbavancin, a new glycopeptide antibiotic with unique pharmacokinetic properties that have allowed clinical development of a weekly dos...
Saved in:
| Published in: | Clinical infectious diseases 2005-02, Vol.40 (3), p.374-380 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c482t-75ee11cca962fc785b721a3a5fd0544dbc3f06f26bbabd040366f994ce022aa83 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c482t-75ee11cca962fc785b721a3a5fd0544dbc3f06f26bbabd040366f994ce022aa83 |
| container_end_page | 380 |
| container_issue | 3 |
| container_start_page | 374 |
| container_title | Clinical infectious diseases |
| container_volume | 40 |
| creator | Raad, Issam Darouiche, Rabih Vazquez, Jose Lentnek, Arnold Hachem, Ray Hanna, Hend Goldstein, Beth Henkel, Tim Seltzer, Elyse |
| description | Background. Catheter-related bloodstream infections (CR-BSIs) are associated with substantial mortality, prolongation of hospital stay, and increased cost of care. Dalbavancin, a new glycopeptide antibiotic with unique pharmacokinetic properties that have allowed clinical development of a weekly dosing regimen, possesses excellent activity against clinically important gram-positive bacteria, suggesting utility in the treatment of patients with CR-BSIs. Methods. A phase 2, open-label, randomized, controlled, multicenter study of 75 adult patients with CR-BSIs compared treatment with intravenous dalbavancin, administered as a single 1000-mg dose followed by a 500-mg dose 1 week later, with intravenous vancomycin, administered twice daily for 14 days. Gram-positive bacteria isolated in this study included coagulase-negative staphylococci (CoNS) and Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA). Results. Infected patients who received weekly dalbavancin (n = 33) had an overall success rate (87.0%; 95% confidence interval [CI], 73.2%–100.0%) that was significantly higher than that of those who received vancomycin (n = 34) (50.0%; 95% CI, 31.5%–68.5%). Adverse events and laboratory abnormalities were generally mild and were comparable for the 2 drugs. Conclusions. Dalbavancin thus appears to be an effective and well-tolerated treatment option for adult patients with CR-BSIs caused by CoNS and S. aureus, including MRSA. |
| doi_str_mv | 10.1086/427283 |
| format | article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_17828427</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>4484094</jstor_id><oup_id>10.1086/427283</oup_id><sourcerecordid>4484094</sourcerecordid><originalsourceid>FETCH-LOGICAL-c482t-75ee11cca962fc785b721a3a5fd0544dbc3f06f26bbabd040366f994ce022aa83</originalsourceid><addsrcrecordid>eNp1kU9v1DAQxSMEon-AT4CQQYJbwE5sxznCUtqKVlRtoRUXa-KMabbZeGs7Fbnw2fFqV10JidOM9H7zZvQmy14w-p5RJT_woipU-SjbZaKscilq9jj1VKicq1LtZHshzCllTFHxNNthQkqlRL2b_TmwtjNgJgJDSy7AYpyIs-QK8bafyGfoG7iHwXQDubxBD8uJWOfJDOINRvT5OfYQsSWfeufaED3CghwPFk3s3JCwMSSxmcihh0V-5kIXu3skZ2nc_cIhPMueWOgDPt_U_ez7l4PL2VF-8u3wePbxJDdcFTGvBCJjxkAtC2sqJZqqYFCCsC0VnLeNKS2VtpBNA01LOS2ltHXNDdKiAFDlfvZu7bv07m7EEPWiCwb7HgZ0Y9CsUoVKGSbwzT_g3I1-SLfpgtW1FGn51s14F4JHq5e-W4CfNKN69Q69fkcCX23cxmaB7Rbb5J-AtxsAgoHe-lXUYctJyVglVve_XnNuXP5_2cs1Mw_R-QeKc8VpzZOcr-UuRPz9IIO_1bIqK6GPrn_q06uLr6c_-Lm-Lv8COkC02w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219965785</pqid></control><display><type>article</type><title>Efficacy and Safety of Weekly Dalbavancin Therapy for Catheter-Related Bloodstream Infection Caused by Gram-Positive Pathogens</title><source>JSTOR Archival Journals and Primary Sources Collection</source><source>Oxford Journals</source><creator>Raad, Issam ; Darouiche, Rabih ; Vazquez, Jose ; Lentnek, Arnold ; Hachem, Ray ; Hanna, Hend ; Goldstein, Beth ; Henkel, Tim ; Seltzer, Elyse</creator><creatorcontrib>Raad, Issam ; Darouiche, Rabih ; Vazquez, Jose ; Lentnek, Arnold ; Hachem, Ray ; Hanna, Hend ; Goldstein, Beth ; Henkel, Tim ; Seltzer, Elyse</creatorcontrib><description>Background. Catheter-related bloodstream infections (CR-BSIs) are associated with substantial mortality, prolongation of hospital stay, and increased cost of care. Dalbavancin, a new glycopeptide antibiotic with unique pharmacokinetic properties that have allowed clinical development of a weekly dosing regimen, possesses excellent activity against clinically important gram-positive bacteria, suggesting utility in the treatment of patients with CR-BSIs. Methods. A phase 2, open-label, randomized, controlled, multicenter study of 75 adult patients with CR-BSIs compared treatment with intravenous dalbavancin, administered as a single 1000-mg dose followed by a 500-mg dose 1 week later, with intravenous vancomycin, administered twice daily for 14 days. Gram-positive bacteria isolated in this study included coagulase-negative staphylococci (CoNS) and Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA). Results. Infected patients who received weekly dalbavancin (n = 33) had an overall success rate (87.0%; 95% confidence interval [CI], 73.2%–100.0%) that was significantly higher than that of those who received vancomycin (n = 34) (50.0%; 95% CI, 31.5%–68.5%). Adverse events and laboratory abnormalities were generally mild and were comparable for the 2 drugs. Conclusions. Dalbavancin thus appears to be an effective and well-tolerated treatment option for adult patients with CR-BSIs caused by CoNS and S. aureus, including MRSA.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1086/427283</identifier><identifier>PMID: 15668859</identifier><identifier>CODEN: CIDIEL</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Administered dose ; Adult ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents - adverse effects ; Anti-Bacterial Agents - therapeutic use ; Antibacterial agents ; Antibiotics ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Bacteremia ; Bacterial diseases ; Biological and medical sciences ; Blood ; Catheters ; Catheters, Indwelling - adverse effects ; Clinical outcomes ; Dosage ; Drug Administration Schedule ; Drug therapy ; Female ; General aspects ; Glycopeptides ; Human bacterial diseases ; Human infectious diseases. Experimental studies and models ; Humans ; Infections ; Infectious diseases ; Major Articles ; Male ; Medical sciences ; Middle Aged ; Pathogens ; Pharmacology. Drug treatments ; Staphylococcal infections, streptococcal infections, pneumococcal infections ; Staphylococcus aureus ; Teicoplanin - adverse effects ; Teicoplanin - analogs & derivatives ; Teicoplanin - therapeutic use ; Vancomycin - adverse effects ; Vancomycin - therapeutic use</subject><ispartof>Clinical infectious diseases, 2005-02, Vol.40 (3), p.374-380</ispartof><rights>Copyright 2005 The Infectious Diseases Society of America</rights><rights>2005 by the Infectious Diseases Society of America 2005</rights><rights>2005 INIST-CNRS</rights><rights>Copyright University of Chicago, acting through its Press Feb 1, 2005</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c482t-75ee11cca962fc785b721a3a5fd0544dbc3f06f26bbabd040366f994ce022aa83</citedby><cites>FETCH-LOGICAL-c482t-75ee11cca962fc785b721a3a5fd0544dbc3f06f26bbabd040366f994ce022aa83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/4484094$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/4484094$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>315,786,790,27957,27958,58593,58826</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16611758$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15668859$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Raad, Issam</creatorcontrib><creatorcontrib>Darouiche, Rabih</creatorcontrib><creatorcontrib>Vazquez, Jose</creatorcontrib><creatorcontrib>Lentnek, Arnold</creatorcontrib><creatorcontrib>Hachem, Ray</creatorcontrib><creatorcontrib>Hanna, Hend</creatorcontrib><creatorcontrib>Goldstein, Beth</creatorcontrib><creatorcontrib>Henkel, Tim</creatorcontrib><creatorcontrib>Seltzer, Elyse</creatorcontrib><title>Efficacy and Safety of Weekly Dalbavancin Therapy for Catheter-Related Bloodstream Infection Caused by Gram-Positive Pathogens</title><title>Clinical infectious diseases</title><addtitle>Clinical Infectious Diseases</addtitle><addtitle>Clinical Infectious Diseases</addtitle><description>Background. Catheter-related bloodstream infections (CR-BSIs) are associated with substantial mortality, prolongation of hospital stay, and increased cost of care. Dalbavancin, a new glycopeptide antibiotic with unique pharmacokinetic properties that have allowed clinical development of a weekly dosing regimen, possesses excellent activity against clinically important gram-positive bacteria, suggesting utility in the treatment of patients with CR-BSIs. Methods. A phase 2, open-label, randomized, controlled, multicenter study of 75 adult patients with CR-BSIs compared treatment with intravenous dalbavancin, administered as a single 1000-mg dose followed by a 500-mg dose 1 week later, with intravenous vancomycin, administered twice daily for 14 days. Gram-positive bacteria isolated in this study included coagulase-negative staphylococci (CoNS) and Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA). Results. Infected patients who received weekly dalbavancin (n = 33) had an overall success rate (87.0%; 95% confidence interval [CI], 73.2%–100.0%) that was significantly higher than that of those who received vancomycin (n = 34) (50.0%; 95% CI, 31.5%–68.5%). Adverse events and laboratory abnormalities were generally mild and were comparable for the 2 drugs. Conclusions. Dalbavancin thus appears to be an effective and well-tolerated treatment option for adult patients with CR-BSIs caused by CoNS and S. aureus, including MRSA.</description><subject>Administered dose</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Bacterial Agents - adverse effects</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibacterial agents</subject><subject>Antibiotics</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Bacteremia</subject><subject>Bacterial diseases</subject><subject>Biological and medical sciences</subject><subject>Blood</subject><subject>Catheters</subject><subject>Catheters, Indwelling - adverse effects</subject><subject>Clinical outcomes</subject><subject>Dosage</subject><subject>Drug Administration Schedule</subject><subject>Drug therapy</subject><subject>Female</subject><subject>General aspects</subject><subject>Glycopeptides</subject><subject>Human bacterial diseases</subject><subject>Human infectious diseases. Experimental studies and models</subject><subject>Humans</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Major Articles</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pathogens</subject><subject>Pharmacology. Drug treatments</subject><subject>Staphylococcal infections, streptococcal infections, pneumococcal infections</subject><subject>Staphylococcus aureus</subject><subject>Teicoplanin - adverse effects</subject><subject>Teicoplanin - analogs & derivatives</subject><subject>Teicoplanin - therapeutic use</subject><subject>Vancomycin - adverse effects</subject><subject>Vancomycin - therapeutic use</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNp1kU9v1DAQxSMEon-AT4CQQYJbwE5sxznCUtqKVlRtoRUXa-KMabbZeGs7Fbnw2fFqV10JidOM9H7zZvQmy14w-p5RJT_woipU-SjbZaKscilq9jj1VKicq1LtZHshzCllTFHxNNthQkqlRL2b_TmwtjNgJgJDSy7AYpyIs-QK8bafyGfoG7iHwXQDubxBD8uJWOfJDOINRvT5OfYQsSWfeufaED3CghwPFk3s3JCwMSSxmcihh0V-5kIXu3skZ2nc_cIhPMueWOgDPt_U_ez7l4PL2VF-8u3wePbxJDdcFTGvBCJjxkAtC2sqJZqqYFCCsC0VnLeNKS2VtpBNA01LOS2ltHXNDdKiAFDlfvZu7bv07m7EEPWiCwb7HgZ0Y9CsUoVKGSbwzT_g3I1-SLfpgtW1FGn51s14F4JHq5e-W4CfNKN69Q69fkcCX23cxmaB7Rbb5J-AtxsAgoHe-lXUYctJyVglVve_XnNuXP5_2cs1Mw_R-QeKc8VpzZOcr-UuRPz9IIO_1bIqK6GPrn_q06uLr6c_-Lm-Lv8COkC02w</recordid><startdate>20050201</startdate><enddate>20050201</enddate><creator>Raad, Issam</creator><creator>Darouiche, Rabih</creator><creator>Vazquez, Jose</creator><creator>Lentnek, Arnold</creator><creator>Hachem, Ray</creator><creator>Hanna, Hend</creator><creator>Goldstein, Beth</creator><creator>Henkel, Tim</creator><creator>Seltzer, Elyse</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7U2</scope></search><sort><creationdate>20050201</creationdate><title>Efficacy and Safety of Weekly Dalbavancin Therapy for Catheter-Related Bloodstream Infection Caused by Gram-Positive Pathogens</title><author>Raad, Issam ; Darouiche, Rabih ; Vazquez, Jose ; Lentnek, Arnold ; Hachem, Ray ; Hanna, Hend ; Goldstein, Beth ; Henkel, Tim ; Seltzer, Elyse</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c482t-75ee11cca962fc785b721a3a5fd0544dbc3f06f26bbabd040366f994ce022aa83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Administered dose</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Bacterial Agents - adverse effects</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibacterial agents</topic><topic>Antibiotics</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Bacteremia</topic><topic>Bacterial diseases</topic><topic>Biological and medical sciences</topic><topic>Blood</topic><topic>Catheters</topic><topic>Catheters, Indwelling - adverse effects</topic><topic>Clinical outcomes</topic><topic>Dosage</topic><topic>Drug Administration Schedule</topic><topic>Drug therapy</topic><topic>Female</topic><topic>General aspects</topic><topic>Glycopeptides</topic><topic>Human bacterial diseases</topic><topic>Human infectious diseases. Experimental studies and models</topic><topic>Humans</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Major Articles</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pathogens</topic><topic>Pharmacology. Drug treatments</topic><topic>Staphylococcal infections, streptococcal infections, pneumococcal infections</topic><topic>Staphylococcus aureus</topic><topic>Teicoplanin - adverse effects</topic><topic>Teicoplanin - analogs & derivatives</topic><topic>Teicoplanin - therapeutic use</topic><topic>Vancomycin - adverse effects</topic><topic>Vancomycin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Raad, Issam</creatorcontrib><creatorcontrib>Darouiche, Rabih</creatorcontrib><creatorcontrib>Vazquez, Jose</creatorcontrib><creatorcontrib>Lentnek, Arnold</creatorcontrib><creatorcontrib>Hachem, Ray</creatorcontrib><creatorcontrib>Hanna, Hend</creatorcontrib><creatorcontrib>Goldstein, Beth</creatorcontrib><creatorcontrib>Henkel, Tim</creatorcontrib><creatorcontrib>Seltzer, Elyse</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Safety Science and Risk</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Raad, Issam</au><au>Darouiche, Rabih</au><au>Vazquez, Jose</au><au>Lentnek, Arnold</au><au>Hachem, Ray</au><au>Hanna, Hend</au><au>Goldstein, Beth</au><au>Henkel, Tim</au><au>Seltzer, Elyse</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and Safety of Weekly Dalbavancin Therapy for Catheter-Related Bloodstream Infection Caused by Gram-Positive Pathogens</atitle><jtitle>Clinical infectious diseases</jtitle><stitle>Clinical Infectious Diseases</stitle><addtitle>Clinical Infectious Diseases</addtitle><date>2005-02-01</date><risdate>2005</risdate><volume>40</volume><issue>3</issue><spage>374</spage><epage>380</epage><pages>374-380</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><coden>CIDIEL</coden><notes>ark:/67375/HXZ-MWSKMV4R-X</notes><notes>istex:F9E9EE8C4E6D0A5CBABED88350B2D4AE81510E0B</notes><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>Background. Catheter-related bloodstream infections (CR-BSIs) are associated with substantial mortality, prolongation of hospital stay, and increased cost of care. Dalbavancin, a new glycopeptide antibiotic with unique pharmacokinetic properties that have allowed clinical development of a weekly dosing regimen, possesses excellent activity against clinically important gram-positive bacteria, suggesting utility in the treatment of patients with CR-BSIs. Methods. A phase 2, open-label, randomized, controlled, multicenter study of 75 adult patients with CR-BSIs compared treatment with intravenous dalbavancin, administered as a single 1000-mg dose followed by a 500-mg dose 1 week later, with intravenous vancomycin, administered twice daily for 14 days. Gram-positive bacteria isolated in this study included coagulase-negative staphylococci (CoNS) and Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA). Results. Infected patients who received weekly dalbavancin (n = 33) had an overall success rate (87.0%; 95% confidence interval [CI], 73.2%–100.0%) that was significantly higher than that of those who received vancomycin (n = 34) (50.0%; 95% CI, 31.5%–68.5%). Adverse events and laboratory abnormalities were generally mild and were comparable for the 2 drugs. Conclusions. Dalbavancin thus appears to be an effective and well-tolerated treatment option for adult patients with CR-BSIs caused by CoNS and S. aureus, including MRSA.</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>15668859</pmid><doi>10.1086/427283</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2005-02, Vol.40 (3), p.374-380 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_17828427 |
| source | JSTOR Archival Journals and Primary Sources Collection; Oxford Journals |
| subjects | Administered dose Adult Aged Aged, 80 and over Anti-Bacterial Agents - adverse effects Anti-Bacterial Agents - therapeutic use Antibacterial agents Antibiotics Antibiotics. Antiinfectious agents. Antiparasitic agents Bacteremia Bacterial diseases Biological and medical sciences Blood Catheters Catheters, Indwelling - adverse effects Clinical outcomes Dosage Drug Administration Schedule Drug therapy Female General aspects Glycopeptides Human bacterial diseases Human infectious diseases. Experimental studies and models Humans Infections Infectious diseases Major Articles Male Medical sciences Middle Aged Pathogens Pharmacology. Drug treatments Staphylococcal infections, streptococcal infections, pneumococcal infections Staphylococcus aureus Teicoplanin - adverse effects Teicoplanin - analogs & derivatives Teicoplanin - therapeutic use Vancomycin - adverse effects Vancomycin - therapeutic use |
| title | Efficacy and Safety of Weekly Dalbavancin Therapy for Catheter-Related Bloodstream Infection Caused by Gram-Positive Pathogens |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T20%3A10%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20Safety%20of%20Weekly%20Dalbavancin%20Therapy%20for%20Catheter-Related%20Bloodstream%20Infection%20Caused%20by%20Gram-Positive%20Pathogens&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Raad,%20Issam&rft.date=2005-02-01&rft.volume=40&rft.issue=3&rft.spage=374&rft.epage=380&rft.pages=374-380&rft.issn=1058-4838&rft.eissn=1537-6591&rft.coden=CIDIEL&rft_id=info:doi/10.1086/427283&rft_dat=%3Cjstor_proqu%3E4484094%3C/jstor_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c482t-75ee11cca962fc785b721a3a5fd0544dbc3f06f26bbabd040366f994ce022aa83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=219965785&rft_id=info:pmid/15668859&rft_jstor_id=4484094&rft_oup_id=10.1086/427283&rfr_iscdi=true |